{
  "source_file": "07_license_cytodyn.txt",
  "provider": "gemini",
  "model": "flash",
  "eval_id": "eval_flash_20251127_163038_038fe6d4",
  "timestamp": "2025-11-27T16:31:53.391983",
  "extraction": {
    "parties": {
      "raw_snippet": "Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\u201cVyera\u201d), and CytoDyn Inc., a Delaware corporation (\u201cCytoDyn\u201d). CytoDyn and Vyera are sometimes referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d",
      "reasoning": "The introductory paragraph clearly identifies and defines the two primary parties to the agreement.",
      "normalized_value": [
        "Vyera Pharmaceuticals, LLC",
        "CytoDyn Inc."
      ]
    },
    "contract_type": {
      "raw_snippet": "COMMERCIALIZATION AND LICENSE AGREEMENT This Commercialization and License Agreement (this \u201cAgreement\u201d) is made effective as of December 17, 2019 (the \u201cEffective Date\u201d) by and between Vyera Pharmaceuticals, LLC, a Delaware limited liability company (\u201cVyera\u201d), and CytoDyn Inc., a Delaware corporation (\u201cCytoDyn\u201d).",
      "reasoning": "The title of the agreement explicitly states 'Commercialization and License Agreement.' The recitals also specify that Vyera will 'Commercialize' Licensed Products 'in accordance with the terms and conditions of this Agreement' and Section 2.1 grants licenses.",
      "normalized_value": "License Agreement"
    },
    "notice_period": {
      "raw_snippet": "",
      "reasoning": "The agreement defines a 'Term' that expires on the 'last day of the Royalty Term' (Section 11.1). Upon this expiration, the license becomes perpetual and royalty-free, rather than the agreement renewing. There is no clause specifying a notice period required to prevent an automatic renewal of the agreement's term.",
      "normalized_value": ""
    },
    "expiration_date": {
      "raw_snippet": "The term of this Agreement (\u201cTerm\u201d) shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article 11, shall expire on the last day of the Royalty Term.\n\u201cRoyalty Term\u201d means the time period beginning with the First Commercial Sale of the Licensed Product in the Territory and continuing until the latest of (a) the expiration of the last Valid Claim Covering the Licensed Product and included in a CytoDyn Patent licensed to Vyera under this Agreement, (b) the date that is ten (10) years from the date of the First Commercial Sale, (c) the expiration of any Regulatory Exclusivity with respect to the Licensed Product and (d) the Biosimilar Entry Date.",
      "reasoning": "Section 11.1 states that the agreement's 'Term' shall 'expire on the last day of the Royalty Term.' Section 1.94 defines 'Royalty Term' as a period contingent on several relative future events. This is a relative term for the agreement's active duration.",
      "normalized_value": "latest of (a) expiration of last Valid Claim, (b) 10 years from First Commercial Sale, (c) expiration of Regulatory Exclusivity, or (d) Biosimilar Entry Date"
    },
    "renewal_term": {
      "raw_snippet": "The term of this Agreement (\u201cTerm\u201d) shall commence upon the Effective Date and, unless earlier terminated pursuant to this Article 11, shall expire on the last day of the Royalty Term. Upon the expiration of the Royalty Term, the license granted to Vyera under Section 2.1 of this Agreement shall become non-exclusive, fully-paid, royalty free, perpetual and irrevocable.",
      "reasoning": "Section 11.1 states that the agreement's 'Term' shall 'expire' rather than automatically renew. Upon this expiration, the license *transforms* into a perpetual, royalty-free license, which is a post-expiration condition, not a renewal of the agreement itself. No explicit renewal term for the agreement is found.",
      "normalized_value": ""
    }
  },
  "usage": {
    "model": "gemini-2.5-flash",
    "input_tokens": 35818,
    "output_tokens": 841
  },
  "latency_seconds": 16.84062886238098
}